Drug intelligence / Profile preview

miR-15a-5p mimic

Development stage
Unknown
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intraperitoneal, Intratumoral, Intravenous, Intravitreal
01

Overview

miR-15a-5p mimic is a synthetic, double-stranded RNA oligonucleotide designed to mimic the activity of endogenous microRNA-15a-5p (miR-15a-5p). As a tumor suppressor, miR-15a-5p is frequently downregulated in various malignancies, including breast cancer, colorectal cancer, pancreatic cancer, and Erdheim-Chester disease. Ectopic expression of miR-15a-5p via transfection of its mimic downregulates key oncogenic and pro-survival targets such as BCL2, BMI1, WEE1, CHK1, YAP1, and CXCL10, thereby inhibiting cell proliferation, inducing cell cycle arrest, and promoting apoptosis. While primarily utilized as a research reagent for functional analysis of miRNA pathways, modified versions of miR-15a mimics (such as the 5-FU-modified CR-001) are being investigated as therapeutic candidates in clinical trials.

Other names
hsa-miR-15a-5p mimichsa-miR15a-5p mimichsa-miR 15a-5p mimicmiR-15a mimicmiR15a mimicmiR 15a mimicmicroRNA-15a-5p mimicmicroRNA15a-5p mimicmicroRNA 15a-5p mimicrno-miR-15a-5p mimicrno-miR15a-5p mimicrno-miR 15a-5p mimic
02

Targets

CXCL10 (C-X-C Motif Chemokine Ligand 10)BMI1 (Polycomb complex protein BMI-1)SMAD2 (Mothers against decapentaplegic homolog 2)CHEK1 (Checkpoint kinase 1)TIGIT (T cell immunoreceptor with Ig and ITIM domains)YAP1 (YES-associated protein–transcriptional enhancer factor domain complex)VEGFA (Vascular endothelial growth factor A)WEE1 (WEE1 G2 checkpoint kinase)

Beyond the preview

Go deeper on miR-15a-5p mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-15a-5p mimic.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call